Equities Analysts Offer Predictions for Sanofi Q1 Earnings

Sanofi (NASDAQ:SNY) – Stock analysts at Zacks Research raised their Q1 2025 earnings per share estimates for Sanofi in a report issued on Wednesday, January 22nd. Zacks Research analyst K. Shah now expects that the company will post earnings of $0.85 per share for the quarter, up from their prior estimate of $0.84. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Zacks Research also issued estimates for Sanofi’s Q2 2025 earnings at $0.94 EPS, Q4 2025 earnings at $1.10 EPS, FY2025 earnings at $4.47 EPS and Q3 2026 earnings at $1.47 EPS.

Separately, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th.

Sanofi Stock Performance

Shares of SNY opened at $52.48 on Monday. The firm has a market cap of $133.19 billion, a P/E ratio of 26.78, a PEG ratio of 1.19 and a beta of 0.57. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm’s 50 day moving average price is $48.70 and its two-hundred day moving average price is $52.20.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Sanofi’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.55 EPS.

Hedge Funds Weigh In On Sanofi

Large investors have recently bought and sold shares of the company. Synergy Asset Management LLC bought a new stake in shares of Sanofi in the fourth quarter worth $25,000. Northwest Investment Counselors LLC acquired a new stake in Sanofi in the 3rd quarter valued at $29,000. Concord Wealth Partners lifted its position in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after buying an additional 363 shares in the last quarter. Fortitude Family Office LLC boosted its stake in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the last quarter. Finally, Sunbelt Securities Inc. grew its holdings in shares of Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after acquiring an additional 313 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.